{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Autophagy", "IBD animal model", "Intestinal inflammation", "Microtubules", "NLRP3 inflammasome", "Naphthoquinone derivatives"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35462013", "DateCompleted": {"Year": "2022", "Month": "05", "Day": "24"}, "DateRevised": {"Year": "2022", "Month": "06", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "04", "Day": "22"}], "Language": ["eng"], "ELocationID": ["10.1016/j.phrs.2022.106233", "S1043-6618(22)00178-5"], "Journal": {"ISSN": "1096-1186", "JournalIssue": {"Volume": "179", "PubDate": {"Year": "2022", "Month": "May"}}, "Title": "Pharmacological research", "ISOAbbreviation": "Pharmacol Res"}, "ArticleTitle": "Naphthoquinone derivatives as P-glycoprotein inducers in inflammatory bowel disease: 2D monolayers, 3D spheroids, and in vivo models.", "Pagination": {"StartPage": "106233", "MedlinePgn": "106233"}, "Abstract": {"AbstractText": ["Inflammatory bowel disease (IBD) represents a chronic inflammation of the gastrointestinal tract characterized by an overreaction of immune responses and damage at the intestinal mucosal barrier. P-glycoprotein (P-gp) plays a key role to protect the intestinal barrier from xenobiotic accumulation and suppressing excessive immune responses. Therefore, induction/activation of P-gp function could serve as a novel therapeutic target to treat IBD. This study aimed to evaluate the potential therapeutic values of naphthoquinone derivatives (NQ-1 - NQ-8) as P-gp modulators to counterbalance intestinal inflammation. The data indicate that NQ-2, NQ-3, and NQ-4 act as P-gp inducers/activators and are recognized as substrates for P-gp. The three derivatives possess anti-inflammatory effects mediated by suppression of NF-\u03baB and HDAC6 activity in Caco2 monolayer cells. Besides, they reversed LPS-induced intestinal barrier dysfunction by enhancing the expression of P-gp and ZO-1 tight junction proteins in a Caco-2 spheroid model. NQ-2, NQ-3, and NQ-4 showed a robust inhibitory effect on IL-1\u03b2 maturation in LPS-primed THP-1 cells. This effect may contribute to alleviate the inflammatory cascades associated with IBD. Distinctively, NQ-2 and NQ-3 exerted anti-NLRP3 inflammasome activity evidenced by the inhibition of CASP-1 activity and the promotion of autophagy. Both compounds induced disruptions of the microtubule network in transfected U2OS-GFP-\u03b1-tubulin cells. Treatment with NQ-2 remarkably attenuated dextran sulfate sodium (DSS)-induced colitis in rats by suppressing changes in colon length, colon mass index, and intestinal histopathology scores. Thus, 1,4-naphthoquinone derivatives such as NQ-2 may provide potential therapeutic anti-inflammatory effects for IBD patients and for other NLRP3-associated inflammatory diseases."], "CopyrightInformation": "Copyright \u00a9 2022 Elsevier Ltd. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany."}], "LastName": "Mahmoud", "ForeName": "Nuha", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany; Home address: Chemistry of Medicinal Plants Department, National Research Centre, 33 El-Bohouth Street, Giza 12622, Egypt."}], "LastName": "Hegazy", "ForeName": "Mohamed-Elamir F", "Initials": "MF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt."}], "LastName": "Wadie", "ForeName": "Walaa", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany."}], "LastName": "Elbadawi", "ForeName": "Mohamed", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Fischer Analytics, Department Fischer Organics, 55413 Weiler, Germany."}], "LastName": "Fleischer", "ForeName": "Edmond", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "MicroCombiChem GmbH, Am Eichelg\u00e4rtchen 36, 56283 Halsenbach, Germany."}], "LastName": "Klinger", "ForeName": "Anette", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Organic Chemistry, University of W\u00fcrzburg, Am Hubland, 97074 W\u00fcrzburg, Germany."}], "LastName": "Bringmann", "ForeName": "Gerhard", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt."}], "LastName": "Khayyal", "ForeName": "Mohamed T", "Initials": "MT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany. Electronic address: efferth@uni-mainz.de."}], "LastName": "Efferth", "ForeName": "Thomas", "Initials": "T"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Pharmacol Res", "NlmUniqueID": "8907422", "ISSNLinking": "1043-6618"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "ATP Binding Cassette Transporter, Subfamily B"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Lipopolysaccharides"}, {"RegistryNumber": "0", "NameOfSubstance": "Naphthoquinones"}, {"RegistryNumber": "9042-14-2", "NameOfSubstance": "Dextran Sulfate"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "ATP Binding Cassette Transporter, Subfamily B"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": [], "DescriptorName": "Caco-2 Cells"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Colitis"}, {"QualifierName": ["metabolism"], "DescriptorName": "Colon"}, {"QualifierName": [], "DescriptorName": "Dextran Sulfate"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Inflammation"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Inflammatory Bowel Diseases"}, {"QualifierName": [], "DescriptorName": "Lipopolysaccharides"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred C57BL"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Naphthoquinones"}, {"QualifierName": [], "DescriptorName": "Rats"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2021", "Month": "10", "Day": "20"}, {"Year": "2022", "Month": "4", "Day": "7"}, {"Year": "2022", "Month": "4", "Day": "19"}, {"Year": "2022", "Month": "4", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "24", "Hour": "20", "Minute": "22"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35462013", "10.1016/j.phrs.2022.106233", "S1043-6618(22)00178-5"]}}], "PubmedBookArticle": []}